{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:46:22Z","timestamp":1791909982872,"version":"4.3.4"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.intimp.2017.10.027","type":"journal-article","created":{"date-parts":[[2017,10,29]],"date-time":"2017-10-29T08:32:38Z","timestamp":1509265958000},"page":"133-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-8830","authenticated-orcid":false,"given":"Soheil","family":"Tavakolpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2017.10.027_bb0005","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","article-title":"The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use","volume":"103","author":"Manson","year":"2009","journal-title":"Respir. Med."},{"key":"10.1016\/j.intimp.2017.10.027_bb0010","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s12325-016-0343-4","article-title":"Management of pemphigus vulgaris","volume":"33","author":"Cholera","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.intimp.2017.10.027_bb0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 guideline for diagnosis and treatment\u2014guided by the European dermatology forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy, Asthma Clin. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: quintiles prize lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0190-9622(03)02738-5","article-title":"Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris","volume":"49","author":"Mimouni","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0190-9622(82)70111-2","article-title":"Death in pemphigus","volume":"7","author":"Ahmed","year":"1982","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0040","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/archderm.1976.01630310024005","article-title":"Pemphigus: a 20-year review of 107 patients treated with corticosteroids","volume":"112","author":"Rosenberg","year":"1976","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.clindermatol.2013.01.005","article-title":"Pemphigus: associations and management guidelines: facts and controversies","volume":"31","author":"Ruocco","year":"2013","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0050","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-4362.1995.tb04450.x","article-title":"Steroid-pulse therapy in pemphigus vulgaris long term eollow-up","volume":"34","author":"Chryssomallis","year":"1995","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0055","first-page":"329","article-title":"Pulse therapy and its modifications in pemphigus: a six year study","volume":"69","author":"Rao","year":"2003","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0060","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2017.10.027_bb0065","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2017.10.027_bb0070","first-page":"353","article-title":"Mycophenolate mofetil\u2014a new atheropreventive drug?","volume":"71","author":"Olejarz","year":"2014","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.intimp.2017.10.027_bb0075","first-page":"210","article-title":"Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris","volume":"12","author":"Vyas","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0080","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus","volume":"142","author":"Beissert","year":"2006","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-3083.1997.d01-407.x","article-title":"Mycophenolate mofetil, azathioprine and cyclophosphamide enhanced efficacy combined with cyclosporine in rat cardiac transplantation","volume":"45","author":"Ostraat","year":"1997","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0090","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/09546634.2014.880395","article-title":"Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus","volume":"26","author":"Doukaki","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.intimp.2017.10.027_bb0100","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4103\/0378-6323.35740","article-title":"Mycophenolate mofetil as adjuvant in pemphigus vulgaris","volume":"73","author":"Sarma","year":"2007","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0105","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1468-3083.2011.04170.x","article-title":"Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study","volume":"26","author":"Ioannides","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0110","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial","volume":"130","author":"Beissert","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archderm.139.6.739","article-title":"Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil","volume":"139","author":"Mimouni","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0120","first-page":"1","article-title":"Mycophenolate mofetil: a dermatologic perspective","volume":"10","author":"Mydlarski","year":"2005","journal-title":"Skin Therapy Lett."},{"key":"10.1016\/j.intimp.2017.10.027_bb0125","first-page":"77","article-title":"Management of pemphigus disease in pregnancy","author":"Tavakolpour","year":"2017","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0130","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine: old drug, new actions","volume":"111","author":"Maltzman","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2017.10.027_bb0135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1468-3083.2012.04717.x","article-title":"Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris","volume":"27","author":"Chams-Davatchi","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/archderm.1969.01610250123031","article-title":"Pemphigus vulgaris","volume":"100","author":"Krakowski","year":"1969","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1046\/j.1468-3083.2002.00504.x","article-title":"Pemphigus vulgaris: a review of treatment over a 19-year period","volume":"16","author":"Ljubojevic","year":"2002","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1468-3083.2010.03753.x","article-title":"High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study","volume":"25","author":"Chaidemenos","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2017.10.027_bb0155","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/0378-6323.82400","article-title":"Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review","volume":"77","author":"Singh","year":"2011","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0160","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1365-2133.2011.10575.x","article-title":"British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011","volume":"165","author":"Meggitt","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0165","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0170","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1046\/j.1365-2036.2002.01297.x","article-title":"Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine","volume":"16","author":"Fraser","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2017.10.027_bb0175","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.2.6146.1190","article-title":"Azathioprine plus prednisone in treatment of pemphigoid","volume":"2","author":"Burton","year":"1978","journal-title":"Br. Med. J."},{"key":"10.1016\/j.intimp.2017.10.027_bb0180","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.V4.2.160.160","article-title":"Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer","volume":"4","author":"Farber","year":"1949","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2017.10.027_bb0185","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archderm.1969.01610250076018","article-title":"Treatment of pemphigus vulgaris with methotrexate","volume":"100","author":"Lever","year":"1969","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0195","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"Gurcan","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0200","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1684\/ejd.2011.1611","article-title":"Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris","volume":"22","author":"Baum","year":"2012","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0205","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archderm.135.10.1275","article-title":"Methotrexate as an adjuvant treatment for pemphigus vulgaris","volume":"135","author":"Smith","year":"1999","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-4362.1973.tb00016.x","article-title":"Use of methotrexate to treat pemphigus foliaceus","volume":"12","author":"Rivitti","year":"1973","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0215","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjd.12474","article-title":"Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients","volume":"169","author":"Tran","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1756285609344375","article-title":"Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms","volume":"2","author":"Awad","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2017.10.027_bb0225","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1067\/S0190-9622(03)00859-4","article-title":"Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus","volume":"49","author":"Cummins","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archderm.135.1.57","article-title":"Pulse intravenous cyclophosphamide therapy in pemphigus","volume":"135","author":"Fleischli","year":"1999","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0235","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-4362.1994.tb01003.x","article-title":"Treatment of oral pemphigus vulgaris","volume":"33","author":"Chrysomallis","year":"1994","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0240","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0245","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2230.2009.03450.x","article-title":"Corticosteroid\/cyclophosphamide pulse treatment in south African patients with pemphigus","volume":"35","author":"Shaik","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0250","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/CCID.S75908","article-title":"Management of pemphigus vulgaris: challenges and solutions","volume":"8","author":"Gregoriou","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0255","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0260","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2017.10.027_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00404-011-1859-0","article-title":"Successful pregnancy after cyclophosphamide therapy for lupus nephritis","volume":"283","author":"Lannes","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.intimp.2017.10.027_bb0270","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2017.10.027_bb0275","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archderm.1960.01580030079010","article-title":"Dermatitis herpetiformis with acantholysis or pemphigus with response to sulfonamides: report of two cases","volume":"82","author":"Winkelmann","year":"1960","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.144.1.25","article-title":"Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"144","author":"Werth","year":"2008","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0285","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/archderm.141.6.699","article-title":"Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"141","author":"Heaphy","year":"2005","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0290","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","article-title":"Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data","volume":"10","author":"Gurcan","year":"2009","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0295","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1159\/000448028","article-title":"Efficacy of Dapsone in the treatment of pemphigus vulgaris: a single-center case study","volume":"232","author":"Baum","year":"2016","journal-title":"Dermatology (Basel, Switz.)"},{"key":"10.1016\/j.intimp.2017.10.027_bb0300","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/archderm.142.5.570","article-title":"Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial","volume":"142","author":"Mentink","year":"2006","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0305","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.intimp.2017.10.027_bb0310","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2006060568","article-title":"Molecular mechanisms of cyclosporin A inhibition of the cytokine-induced matrix metalloproteinase-9 in glomerular mesangial cells","volume":"18","author":"Doller","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0315","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2174\/1568026033451916","article-title":"Regulation of MAPK signaling pathways through immunophilin-ligand complex","volume":"3","author":"Matsuda","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.intimp.2017.10.027_bb0320","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/archderm.136.7.868","article-title":"Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus","volume":"136","author":"Ioannides","year":"2000","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0325","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0190-9622(08)81506-X","article-title":"The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study","volume":"30","author":"Lapidoth","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0330","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1365-2133.2003.05665.x","article-title":"Guidelines for the management of pemphigus vulgaris","volume":"149","author":"Harman","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0335","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(05)66829-8","article-title":"Pemphigus","volume":"366","author":"Bystryn","year":"2005","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.intimp.2017.10.027_bb0340","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/OGX.0b013e3181bea089","article-title":"Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes","volume":"64","author":"Kardos","year":"2009","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.intimp.2017.10.027_bb0345","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0190-9622(90)70352-I","article-title":"Topical cyclosporine for oral mucosal disorders","volume":"23","author":"Eisen","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0350","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.bdj.4812523","article-title":"Gingival lesions as a first symptom of pemphigus vulgaris in pregnancy","volume":"199","author":"Lopez-Jornet","year":"2005","journal-title":"Br. Dent. J."},{"key":"10.1016\/j.intimp.2017.10.027_bb0355","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1468-3083.2004.00980.x","article-title":"Topical tacrolimus (protopic) for the treatment of a localized pemphigus foliaceus","volume":"18","author":"Termeer","year":"2004","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0360","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2230.2004.01499.x","article-title":"Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris","volume":"29","author":"Gach","year":"2004","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0365","first-page":"142","article-title":"Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris","volume":"13","author":"Hodgson","year":"2003","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0370","first-page":"684","article-title":"Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial","volume":"9","author":"Iraji","year":"2010","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0375","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1468-3083.2010.03610.x","article-title":"Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris","volume":"24","author":"Mignogna","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0380","first-page":"667","article-title":"Pemphigus vulgaris: a case-based update","volume":"71","author":"Ben Lagha","year":"2005","journal-title":"J. Can. Dent. Assoc."},{"key":"10.1016\/j.intimp.2017.10.027_bb0385","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jamadermatol.2014.3674","article-title":"Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris","volume":"151","author":"Vinay","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0390","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1067\/mjd.2000.109297","article-title":"The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris","volume":"43","author":"Turner","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0395","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/archderm.1979.04010060036025","article-title":"Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris","volume":"115","author":"Auerbach","year":"1979","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0400","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1473-0502(02)00095-2","article-title":"Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid","volume":"28","author":"Mazzi","year":"2003","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.intimp.2017.10.027_bb0405","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0190-9622(90)70004-2","article-title":"Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies","volume":"22","author":"Tan-Lim","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0410","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1744-9987.1997.tb00032.x","article-title":"The steroid-sparing effect of long-term plasmapheresis in pemphigus: an update","volume":"1","author":"Sondergaard","year":"1997","journal-title":"Ther. Apher."},{"key":"10.1016\/j.intimp.2017.10.027_bb0415","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1744-9987.1997.tb00037.x","article-title":"Plasmapheresis for the treatment of pemphigus vulgaris and bullous pemphigoid","volume":"1","author":"Yamada","year":"1997","journal-title":"Ther. Apher."},{"key":"10.1016\/j.intimp.2017.10.027_bb0420","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1346-8138.2000.tb02187.x","article-title":"A case of pemphigus vulgaris successfully treated with single filtration plasmapheresis: a correlation of clinical disease activity with serum antibody levels","volume":"27","author":"Yano","year":"2000","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0425","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.transci.2013.01.008","article-title":"Resistant oral mucosal lesions in pemphigus vulgaris responsive to double filtration plasmapheresis: first case report from Turkey","volume":"48","author":"Savk","year":"2013","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.intimp.2017.10.027_bb0430","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/archderm.134.6.706","article-title":"Immunoapheresis in paraneoplastic pemphigus","volume":"134","author":"Schoen","year":"1998","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0435","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","article-title":"Immunoadsorption in dermatology","volume":"16","author":"Meyersburg","year":"2012","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.intimp.2017.10.027_bb0440","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00403-009-1024-9","article-title":"Immunoadsorption in dermatology","volume":"302","author":"Schmidt","year":"2010","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2017.10.027_bb0445","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/art.38107","article-title":"Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response","volume":"65","author":"Melet","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2017.10.027_bb0450","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2017.10.027_bb0455","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/s10165-009-0244-3","article-title":"Analysis of cytokine production patterns of peripheral blood mononuclear cells from a rheumatoid arthritis patient successfully treated with rituximab","volume":"20","author":"Yamamoto","year":"2010","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0460","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0465","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.intimp.2017.10.027_bb0470","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids","volume":"151","author":"Ingen-Housz-Oro","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0475","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.13823","article-title":"Paradoxical worsening of pemphigus vulgaris following rituximab therapy","volume":"173","author":"Feldman","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0480","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","article-title":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients","volume":"68","author":"Leshem","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0485","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.174379","article-title":"Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study","volume":"82","author":"Sharma","year":"2016","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0490","first-page":"2","article-title":"Exacerbation of pemphigus foliaceus in a child after rituximab treatment","volume":"e05","author":"Parish","year":"2016","journal-title":"Transl. Sci."},{"key":"10.1016\/j.intimp.2017.10.027_bb0495","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0500","first-page":"1","article-title":"Rituximab treatment of pemphigus in women of childbearing age: experience with two patients","author":"Lake","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.intimp.2017.10.027_bb0505","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.14119","article-title":"Pregnancy outcome after rituximab treatment before conception in patients affected by severe pemphigus vulgaris\/superficialis","author":"Vassallo","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0510","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.intimp.2017.10.027_bb0515","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jaad.2008.01.007","article-title":"Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus","volume":"58","author":"Czernik","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0520","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","article-title":"High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases","volume":"38","author":"Ishii","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2017.10.027_bb0525","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/1735-1995.183992","article-title":"The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: a review of literature","volume":"21","author":"Tavakolpour","year":"2016","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.intimp.2017.10.027_bb0530","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.intimp.2005.11.002","article-title":"Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases","volume":"6","author":"Daoud","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0535","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.12280","article-title":"Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin","volume":"40","author":"Kawakami","year":"2013","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0540","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1111\/ijd.12128","article-title":"A resistant case of pemphigus gestationis successfully treated with intravenous immunoglobulin plus cyclosporine","volume":"53","author":"Hapa","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0545","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajd.12422","article-title":"IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects","volume":"57","author":"Svecova","year":"2016","journal-title":"Aust. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0550","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2015.04.038","article-title":"The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis","volume":"73","author":"Atzmony","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0555","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.2002.01967.x","article-title":"High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders","volume":"129","author":"Jolles","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0560","doi-asserted-by":"crossref","DOI":"10.5070\/D3236035399","article-title":"Rituximab administration in a patient with pemphigus vulgaris following reactivation of occult hepatitis B virus infection","volume":"23","author":"Tavakolpour","year":"2017","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.intimp.2017.10.027_bb0565","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2017.10.027_bb0570","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.intimp.2017.10.027_bb0575","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/CDLI.8.5.859-863.2001","article-title":"Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases","volume":"8","author":"Hemming","year":"2001","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0580","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","article-title":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions","volume":"23","author":"Bichuetti-Silva","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0585","first-page":"403","article-title":"Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris","volume":"73","author":"Sheehan","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.intimp.2017.10.027_bb0590","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-4632.2010.04870.x","article-title":"Recalcitrant pemphigus vulgaris: aseptic meningitis associated with intravenous immunoglobulin therapy and successful treatment with rituximab","volume":"52","author":"Ventura","year":"2013","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0595","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2017.10.027_bb0600","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.intimp.2017.10.027_bb0605","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1523-1747.2000.00835.x","article-title":"In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis","volume":"114","author":"Feliciani","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0610","first-page":"220","volume":"13","author":"Ameglio","year":"1999","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.intimp.2017.10.027_bb0615","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2133.2005.06744.x","article-title":"Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab","volume":"153","author":"Jacobi","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0620","first-page":"245","article-title":"Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept","volume":"74","author":"Berookhim","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.intimp.2017.10.027_bb0625","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archderm.141.6.680","article-title":"Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser","volume":"141","author":"Lin","year":"2005","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0630","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2006.08.041","article-title":"Pemphigus foliaceus treated with etanercept","volume":"55","author":"Gubinelli","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0635","first-page":"940","article-title":"Successful treatment of pemphigus vulgaris with etanercept in four patients","volume":"8","author":"Shetty","year":"2009","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0640","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.jaad.2011.05.029","article-title":"Infliximab therapy failure in two patients with pemphigus vulgaris","volume":"67","author":"Garcia-Rabasco","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0645","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjd.13350","article-title":"A multi-centered randomized trial of the treatment of pemphigus vulgaris patients with infliximab and prednisone compared to prednisone alone","volume":"172","author":"Hall","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0650","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/08916934.2012.697593","article-title":"Cytokine networks in pemphigus vulgaris: an integrated viewpoint","volume":"45","author":"Giordano","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2017.10.027_bb0655","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cyto.2014.11.002","article-title":"The dual nature of interleukin-10 in pemphigus vulgaris","volume":"73","author":"Cho","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2017.10.027_bb0660","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2017.10.027_bb0665","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/dth.12327","article-title":"Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus","volume":"29","author":"Tavakolpour","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2017.10.027_bb0670","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.intimp.2016.02.020","article-title":"Interleukin 21 as a new possible player in pemphigus: is it a suitable target?","volume":"34","author":"Tavakolpour","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0675","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.intimp.2016.11.005","article-title":"The possible role of interleukin-35 and its therapeutic potential in pemphigus","volume":"42","author":"Tavakolpour","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0680","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.intimp.2016.04.031","article-title":"The dual nature of retinoic acid in pemphigus and its therapeutic potential: special focus on all-trans retinoic acid","volume":"36","author":"Tavakolpour","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0685","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/08916930400002386","article-title":"The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway","volume":"37","author":"Toubi","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2017.10.027_bb0690","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/490148","article-title":"CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis","volume":"2012","author":"Alaaeddine","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0695","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/sji.12428","article-title":"Blockage of T cell activation via anti-CD40 and anti-CD154 monoclonal antibodies can possibility treat alopecia areata","volume":"83","author":"Tavakolpour","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0700","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.jid.5700016","article-title":"Tolerance induction by the blockade of CD40\/CD154 interaction in pemphigus vulgaris mouse model","volume":"126","author":"Aoki-Ota","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0705","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.intimp.2017.10.027_bb0710","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/269756","article-title":"Coinhibitory molecules in autoimmune diseases","volume":"2012","author":"Watanabe","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0715","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.bmt.1704679","article-title":"High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory pemphigus foliaceus","volume":"34","author":"Oyama","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2017.10.027_bb0720","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11684-008-0036-8","article-title":"Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus","volume":"2","author":"Sun","year":"2008","journal-title":"Front. Med. China"},{"key":"10.1016\/j.intimp.2017.10.027_bb0725","first-page":"785","article-title":"Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning","volume":"14","author":"Suslova","year":"2010","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2017.10.027_bb0730","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/ijd.13461","article-title":"Application of autologous hematopoietic stem cell transplantation for pemphigus","volume":"56","author":"Wang","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0735","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0019-5154.92667","article-title":"Allogenic hematopoietic stem cell transplantation in pemphigus vulgaris: a single-center experience","volume":"57","author":"Vanikar","year":"2012","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0740","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0745","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0750","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.smim.2006.04.004","article-title":"BAFF, APRIL and human B cell disorders","volume":"18","author":"Tangye","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0755","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2133.2006.07305.x","article-title":"Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris","volume":"155","author":"Asashima","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0760","first-page":"16","article-title":"Investigation of serum APRIL and BAFF levels in pemphigus vulgaris patients in Southern Iran","volume":"14","author":"Torkamani","year":"2011","journal-title":"Iran. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0765","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/exd.12421","article-title":"B-cell activating factor detected on both naive and memory B cells in bullous pemphigoid","volume":"23","author":"Qian","year":"2014","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0770","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0775","doi-asserted-by":"crossref","first-page":"23778","DOI":"10.1074\/jbc.M501365200","article-title":"Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization","volume":"280","author":"Berkowitz","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2017.10.027_bb0780","doi-asserted-by":"crossref","first-page":"12524","DOI":"10.1074\/jbc.M808204200","article-title":"Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in pemphigus acantholysis","volume":"284","author":"Lee","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2017.10.027_bb0785","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/sj.jid.5701080","article-title":"Induction of p38MAPK and HSP27 phosphorylation in pemphigus patient skin","volume":"128","author":"Berkowitz","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0790","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2353\/ajpath.2008.080391","article-title":"Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin","volume":"173","author":"Berkowitz","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0795","doi-asserted-by":"crossref","first-page":"12855","DOI":"10.1073\/pnas.0602973103","article-title":"p38MAPK inhibition prevents disease in pemphigus vulgaris mice","volume":"103","author":"Berkowitz","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2017.10.027_bb0800","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.12.010","article-title":"Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering","volume":"85","author":"Yoshida","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2017.10.027_bb0805","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1074\/jbc.M110.172874","article-title":"p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris","volume":"286","author":"Mao","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2017.10.027_bb0810","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1038\/sj.emboj.7601224","article-title":"Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin","volume":"25","author":"Williamson","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2017.10.027_bb0815","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1074\/jbc.M112.438010","article-title":"A pathophysiologic role for epidermal growth factor receptor in pemphigus acantholysis","volume":"288","author":"Bektas","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2017.10.027_bb0820","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/138920208785699553","article-title":"Gene polymorphisms and pharmacogenetics in rheumatoid arthritis","volume":"9","author":"Rego-Perez","year":"2008","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.intimp.2017.10.027_bb0825","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3748\/wjg.v20.i13.3534","article-title":"Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase?","volume":"20","author":"Stocco","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0830","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/138920011795101840","article-title":"Clinical pharmacogenetics of methotrexate","volume":"12","author":"Castaldo","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.intimp.2017.10.027_bb0835","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/0091270009357429","article-title":"Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients","volume":"50","author":"Zhao","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0840","first-page":"2350","article-title":"High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease","volume":"97","author":"Martinez-Borra","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0845","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/ijd.12768","article-title":"Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity","volume":"54","author":"Barnadas","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.10.027_bb0850","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.imlet.2017.08.002","article-title":"Towards personalized medicine for patients with autoimmune diseases: opportunities and challenges","volume":"190","author":"Tavakolpour","year":"2017","journal-title":"Immunol. Lett."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:50:49Z","timestamp":1791906649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576917304058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":170,"alternative-id":["S1567576917304058"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.10.027","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}